Lupin gets nod to market Bromfenac Ophthalmic Solution

16 Aug 2023 Evaluate

Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bromfenac Ophthalmic Solution, 0.09%, to market a generic equivalent of Bromday Ophthalmic Solution, 0.09%, of Bausch & Lomb Inc. This product will be manufactured at Lupin’s Pithampur facility in India. Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of $11 million in the U.S. (IQVIA MAT June 2023).  

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2145.50 13.70 (0.64%)
30-Jan-2026 13:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1602.00
Dr. Reddys Lab 1215.00
Cipla 1324.00
Zydus Lifesciences 886.30
Lupin 2145.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×